The prevalence of the JAK2 mutations is higher in SVT than in usual VTE (32.8% v.s. 0.88%), and it is found in almost all patients (94.7%) with MPN and thrombosis in unusual sites [49,50]. Here, JAK2 is linked to myeloproliferative disorder.